Drug Database
Back to search

Switzerland· 34497001

Angina MCC, Lutschtabletten

A cetylpyridinium product, registered in Switzerland by Streuli Pharma AG and dispensed under Swissmedic category D. The same ATC class is registered in 4 of our 19 countries.

Cat D (Swissmedic)ATC R02AA06

Checked against the register on

Informational only — not a medical device.

SOURCE REGISTER · CHPublic registernormalisedAngina MCC, LutschtablettenATCR02AA06REGISTER NO.34497001PACKS LISTED0CHECKEDJune 26, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about AnginaAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Cetylpyridinium is registered in 4 of 19 countries.

Countries holding a registration under ATC R02AA06 (cetylpyridinium), each read from that country’s own register.

  • This record: Switzerland
  • 3 of them publish a price we can compare per daily dose
Search cetylpyridinium products by name

Cetylpyridinium · ATC R02AA06

4 / 19 countries

  • Canada
  • Czechiaprice
  • Polandprice
  • Switzerlandprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

Manufacturer
Streuli Pharma AG
Country
Switzerland (CH)
ATC code
R02AA06
ATC class
Cetylpyridinium
Swissmedic category
D
Reimbursed
No
Last checked
June 26, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

1 interaction on record for cetylpyridinium.

Graded by severity as the source publishes them — 1 moderate. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check cetylpyridinium against other medicinesHow interaction checks work

Cetylpyridinium · interactions on record

1 record

  • 1 moderate

Most severe, free to view

  • Hyaluronic acidM09AX01moderate
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same class

Other records under R02AA06

Cetylpyridinium, as other registers publish it.

All cetylpyridinium products

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of the issuing authority. This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/8a5f498b-5227-4fcc-9215-870836e28246
GET /v1/drugs/8a5f498b-5227-4fcc-9215-870836e28246?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "source": "swissmedic_auth",
  "heilmittelcode": "Synthetika"
}
API referenceMCP serverPlans

See everything about cetylpyridinium.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console